The Procter & Gamble Company

NYSE:PG Rapport sur les actions

Capitalisation boursière : US$355.1b

Procter & Gamble Bilan de santé

Santé financière contrôle des critères 2/6

Procter & Gamble possède un total de capitaux propres de $54.7B et une dette totale de $37.0B, ce qui porte son ratio d'endettement à 67.7%. Son actif total et son passif total sont $128.4B et de $73.6B. L'EBIT de Procter & Gamble est $22.0B ce qui fait que son ratio de couverture des intérêts 51.5. Elle dispose de liquidités et de placements à court terme de $12.3B.

Informations clés

67.65%

Ratio d'endettement

US$37.03b

Dette

Ratio de couverture des intérêts51.5x
Argent liquideUS$12.31b
Fonds propresUS$54.73b
Total du passifUS$73.65b
Total des actifsUS$128.38b

Mises à jour récentes de la santé financière

Pas de mise à jour

Recent updates

Mise à jour du récit • Jun 16

PG: Cost Productivity And AI Investments Will Support Future Shareholder Returns

Analysts have slightly reduced their price target on Procter & Gamble to about $163.43 from about $163.77, reflecting small adjustments to revenue growth expectations, profit margin assumptions and the projected future P/E multiple. What's in the News P&G raised its quarterly dividend by 3% to US$1.0885 per share, marking the 70th consecutive annual increase, and plans to return about US$15b to shareholders in fiscal 2026 through roughly US$10b in dividends and US$5b in share repurchases.
Mise à jour du récit • Jun 01

PG: Cost Productivity And Portfolio Strength Will Support Future Shareholder Returns

Analysts have slightly reduced their price target on Procter & Gamble to $163.77 from $164.09, reflecting updated assumptions around discount rates, revenue growth, profit margins, and future P/E multiples. What's in the News P&G reported fiscal Q3 2026 net sales of US$21.24b with 3% organic sales growth and core EPS of US$1.59, ahead of analyst expectations, while maintaining full year 2026 guidance for core EPS of US$6.83 to US$7.09 and organic sales growth of 1% to 5% (source: Q3 2026 earnings reports).
Seeking Alpha • May 28

Procter & Gamble: Priced Like A Hyper Growth Tech Stock

Summary Procter & Gamble is reiterated a Sell due to overvaluation and a premature recovery thesis despite recent organic sales growth. Q3 showed encouraging 7% net sales growth and broad-based organic gains, but margins continued to contract and profitability remains under pressure. Procter & Gamble left full-year guidance unchanged, signaling tepid expectations for organic sales and core EPS growth, with management hinting at Middle East headwinds. Share buybacks fell sharply despite strong cash flow, suggesting management may see limited upside or overvaluation at current levels. Read the full article on Seeking Alpha
Mise à jour du récit • May 04

PG: Brand Partnerships And Product Pipeline Will Support Future Shareholder Returns

Analysts have trimmed their Procter & Gamble price target slightly to about $164.09, reflecting modestly lower assumptions for revenue and profit margins while applying a slightly higher future P/E outlook. What's in the News P&G maintained fiscal 2026 guidance, with all-in sales growth expected in a 1% to 5% range and diluted EPS growth targeted in a 1% to 6% range versus fiscal 2025 diluted EPS of US$6.51 (Corporate guidance).
Mise à jour du récit • Apr 20

PG: Buybacks And Brand Partnerships Will Support Future Shareholder Returns

Analysts have slightly reduced their price target on Procter & Gamble to $164.18 from $166.95, reflecting modestly lower assumptions for revenue growth, profit margins, fair value, and future P/E multiples. What's in the News P&G revised its fiscal 2026 diluted EPS growth outlook to a range of 1% to 6%, from a prior range of 3% to 9%, citing higher non core restructuring charges, while keeping all in sales growth guidance at 1% to 5% versus the prior year (Corporate guidance).
Mise à jour du récit • Apr 05

PG: Share Repurchases And Premium Portfolio Refresh Will Support Future Returns

Analysts have slightly reduced their average price target for Procter & Gamble to about $167 from $168, reflecting updated views on margins and forward P/E assumptions while keeping core growth expectations largely intact. What's in the News OLAY shared new skin aging research at the 2026 American Academy of Dermatology meeting, focusing on cell adhesion as a key factor in visible aging and applying these findings to peptide based products across the Regenerist line and the new Regenerist Treatments collection (Product announcement).
Mise à jour du récit • Mar 22

PG: Product Refresh And Buybacks Will Support Future Earnings Resilience

Analysts kept their Procter & Gamble price target steady at $168. This reflects largely unchanged views on fair value, discount rate, revenue growth, profit margin, and future P/E assumptions.
Mise à jour du récit • Mar 08

PG: Brand Refresh And Buybacks Will Support Stable Earnings Outlook

Analysts have maintained their Procter & Gamble price target at $168, reflecting unchanged assumptions around revenue growth, profit margins, and future P/E. This suggests that recent research has not materially shifted their valuation view.
Mise à jour du récit • Feb 21

PG: Brand Activity And Buybacks Will Support Stable Margins And Outlook

Analysts have nudged their price target for Procter & Gamble higher to $168.00 from $167.45, reflecting updated assumptions for revenue growth, slightly higher profit margins and a marginally lower future P/E multiple. What's in the News Tide launched Tide evo, a 100% concentrated, waterless laundry tile with six cleaning layers and no plastic bottles, positioned to address demand for products that align with hygiene and sustainability preferences in the U.S. (Product related announcement) Head & Shoulders introduced BARE Itchy Scalp Relief Serum, aimed at providing clinically tested dandruff protection and itch relief between washes, with a nationwide U.S. launch planned for January 2026.
Mise à jour du récit • Feb 07

PG: Premium Brand Extensions And Stable Margins Will Support A Balanced Outlook

Analysts have nudged their price target on Procter & Gamble slightly higher to US$167.45 from about US$165.32, reflecting updated assumptions for fair value, discount rate, revenue growth, profit margins and future P/E. What's in the News Old Spice launched the Spice Alchemist collection, a premium cologne-infused deodorant, body wash and body mist line positioned against high end fragrances.
Mise à jour du récit • Jan 25

Q2 2026 Update

Update narrative with most recent financial statements.
Mise à jour du récit • Jan 23

PG: Share Repurchases And Margin Pressures Will Shape A Balanced Outlook

Analysts have trimmed their price target on Procter & Gamble to US$165 from US$168, citing updated views on revenue growth, profit margins, and the future P/E multiple. What's in the News P&G updated its fiscal 2026 guidance, keeping all in sales growth for the year in a range of 1% to 5% versus the prior year, while lowering the diluted EPS growth outlook to 1% to 6% from the previous 3% to 9% range, citing higher non core restructuring charges versus fiscal 2025 diluted EPS of US$6.51 (Corporate guidance).
Mise à jour du récit • Jan 07

PG: Share Repurchase Will Support Future Upside With Stable Long Term Outlook

Narrative Update on Procter & Gamble The analyst price target for Procter & Gamble has shifted slightly, with updated assumptions around fair value at about $168.13, discount rate at 6.96%, revenue growth at roughly 3.12%, profit margin near 19.58%, and future P/E around 26.08x, as analysts fine tune their models on the company. What's in the News Pantene is partnering again with social media creator Alix Earle to promote the Abundant & Strong 3-Step System, including limited-edition Alix x Pantene Kits that bundle the three products with a free cosmetics bag and hairbrush for a limited time (product-related announcement).
Mise à jour du récit • Dec 16

PG: Share Repurchase Will Support Future Upside Amid Stable Long Term Outlook

Analysts have nudged their price target for Procter & Gamble slightly lower to approximately $168.50 from about $169.05, reflecting modestly softer long term revenue growth expectations that are only partially offset by a marginally improved profit margin outlook and a slightly lower assumed future valuation multiple. What's in the News Pantene launched the Abundant & Strong Collection, a three step system clinically shown to reduce hair loss by up to 85% by targeting scalp oxidative stress with a Pro Vitamin Complex plus Niacinamide technology.
Mise à jour du récit • Dec 02

PG: Share Repurchase And New Collections Will Drive Continued Momentum

Procter & Gamble's analyst price target remains unchanged at $169.05 as analysts maintain stable estimates based on consistent fair value metrics and minimal adjustments to key financial assumptions. What's in the News Pantene launches the Abundant & Strong Collection, a new three-step system designed to reduce hair loss by up to 85% and promote stronger, denser hair using antioxidant technology.
Mise à jour du récit • Nov 18

PG: Share Buybacks And New Guidance Will Support Steady Uptrend

Analysts have maintained Procter & Gamble's price target at $169.05 per share. There have been only minor adjustments to underlying valuation factors, supporting a steady outlook for the company.
Mise à jour du récit • Nov 03

PG: Share Buyback And Product Rollout Will Drive Long-Term Upside

Analysts have slightly raised their price target for Procter & Gamble to $169.05 from $168.64. They cite incremental improvements in revenue growth forecasts even as profit margin projections moderate.
Mise à jour du récit • Oct 20

Rising Consumer Confidence And Product Investment Will Expand US Markets

Analysts have slightly lowered their price target for Procter & Gamble from $170.95 to $168.64 per share. They cite modest reductions in projected revenue growth, which are partially offset by improved profit margins and valuation multiples.
Article d’analyse • Aug 06

The Procter & Gamble Company (NYSE:PG) Just Reported Full-Year Earnings: Have Analysts Changed Their Mind On The Stock?

NYSE:PG 1 Year Share Price vs Fair Value Explore Procter & Gamble's Fair Values from the Community and select yours The...
User avatar
Nouveau récit • Jul 21

Procter & Gamble: A Dividend Giant Facing Slowing Growth

United States: 48.21%1-Year Revenue Growth = 4.65%
Article d’analyse • Jun 27

The Procter & Gamble Company (NYSE:PG) Shares Could Be 21% Below Their Intrinsic Value Estimate

Key Insights The projected fair value for Procter & Gamble is US$200 based on 2 Stage Free Cash Flow to Equity Procter...
Seeking Alpha • Apr 22

Procter & Gamble: Hold This Stodgy Stalwart

Summary Procter & Gamble is a global consumer product leader, with a strong market presence and consistent, albeit slow, growth in revenue and earnings. Despite being overvalued, PG's profitability remains robust, with reliable cash flow and a solid gross profit margin above industry medians. PG's valuation poses a risk, with a high PEG ratio indicating slow growth, yet it maintains a decent dividend yield and outpaces peers in performance. PG is a safe investment but lacks excitement; it's a hold due to its steady but lethargic growth and overvaluation concerns. Read the full article on Seeking Alpha

Analyse de la situation financière

Passif à court terme: Les actifs à court terme de PG ( $28.0B ) ne couvrent pas ses passifs à court terme ( $38.2B ).

Passif à long terme: Les actifs à court terme de PG ( $28.0B ) ne couvrent pas ses passifs à long terme ( $35.4B ).

Historique et analyse du ratio d'endettement

Niveau d'endettement: Le ratio dette nette/capitaux propres de PG ( 45.2% ) est considéré comme élevé.

Réduire la dette: Le ratio d'endettement de PG est passé de 63.6% à 67.7% au cours des 5 dernières années.

Couverture de la dette: La dette de PG est bien couverte par le flux de trésorerie opérationnel ( 52.4% ).

Couverture des intérêts: Les paiements d'intérêts de PG sur sa dette sont bien couverts par l'EBIT ( 51.5 x couverture).

Bilan

Découvrir des entreprises saines

7D

1Y

7D

1Y

7D

1Y

Analyse de l'entreprise et données financières

DonnéesDernière mise à jour (heure UTC)
Analyse de l'entreprise2026/06/17 22:12
Cours de l'action en fin de journée2026/06/17 00:00
Les revenus2026/03/31
Revenus annuels2025/06/30

Sources de données

Les données utilisées dans notre analyse de l'entreprise proviennent de S&P Global Market Intelligence LLC. Les données suivantes sont utilisées dans notre modèle d'analyse pour générer ce rapport. Les données sont normalisées, ce qui peut entraîner un délai avant que la source ne soit disponible.

PaquetDonnéesCadre temporelExemple de source américaine *
Finances de l'entreprise10 ans
  • Compte de résultat
  • Tableau des flux de trésorerie
  • Bilan
Estimations consensuelles des analystes+3 ans
  • Prévisions financières
  • Objectifs de prix des analystes
Prix du marché30 ans
  • Cours des actions
  • Dividendes, scissions et actions
Propriété10 ans
  • Actionnaires principaux
  • Délits d'initiés
Gestion10 ans
  • L'équipe dirigeante
  • Conseil d'administration
Principaux développements10 ans
  • Annonces de l'entreprise

* Exemple pour les titres américains ; pour les titres non américains, des formulaires réglementaires et des sources équivalentes sont utilisés.

Sauf indication contraire, toutes les données financières sont basées sur une période annuelle mais mises à jour trimestriellement. C'est ce qu'on appelle les données des douze derniers mois (TTM) ou des douze derniers mois (LTM). En savoir plus.

Modèle d'analyse et flocon de neige

Les détails du modèle d’analyse utilisé pour générer ce rapport sont disponibles sur notre page Github; nous proposons également des guides expliquant comment utiliser nos rapports et des tutoriels sur Youtube.

Découvrez l'équipe de classe mondiale qui a conçu et construit le modèle d'analyse Simply Wall St.

Indicateurs de l'industrie et du secteur

Nos indicateurs de secteur et de section sont calculés toutes les 6 heures par Simply Wall St. Les détails de notre processus sont disponibles sur Github.

Sources des analystes

The Procter & Gamble Company est couverte par 42 analystes. 23 de ces analystes ont soumis les estimations de revenus ou de bénéfices utilisées comme données d'entrée dans notre rapport. Les soumissions des analystes sont mises à jour tout au long de la journée.

AnalysteInstitution
Christopher GrajaArgus Research Company
Lauren LiebermanBarclays
Bethan DaviesBerenberg